The Global point of care diagnostic market was valued at $23.7 billion in 2022 and is projected to reach $46.7 billion by 2030, growing at a CAGR of 14.5% during the forecast period. The global point of care diagnostic market refers to the market for medical diagnostic tests that can be performed near the patient, rather than in a centralized laboratory. These tests are typically conducted in a doctor's office, hospital room, or at home, and provide fast and accurate results to aid in diagnosis and treatment decisions.

Browse 217 market data Tables and 94 Figures spread through 322 Pages and in-depth TOC on "Point of Care Diagnostic Market Size, Share & Trends Estimation Report By Outlook, By Region, And Segment Forecasts, 2022 - 2030" View detailed Table of Content here-https://www.contrivedatuminsights.com/product-report/point-of-care-diagnostic-market-248663/

Chronic diseases such as diabetes, cardiovascular diseases, and cancer are on the rise worldwide. Point of care diagnostics allow for quicker and more convenient testing, enabling earlier diagnosis and better management of these diseases. In emergency situations, timely and accurate diagnosis is critical to provide appropriate treatment. Point of care diagnostics can provide fast results and help healthcare providers make informed decisions quickly.

Market Dynamics

The market for point of care diagnostics has been growing rapidly in recent years, driven by factors such as the increasing prevalence of chronic diseases, the need for rapid and accurate diagnostic testing in emergency situations, and the development of portable, easy-to-use diagnostic devices.

While many point of care diagnostic tests are highly accurate and reliable, some tests may not be as accurate or sensitive as those performed in a central laboratory. This could lead to incorrect diagnoses and treatment decisions, potentially impacting patient outcomes. The regulatory environment for point of care diagnostics varies widely across different countries and regions, which can create confusion and uncertainty for manufacturers and users. This lack of standardization could also impact the quality and reliability of some point of care diagnostic tests.

Ensuring the quality and consistency of point of care diagnostic tests can be challenging, particularly in low-resource settings or in regions with limited regulatory oversight. Standardization of testing protocols and quality control measures is necessary to ensure accurate and reliable results. Point of care diagnostic tests require proper training and education for healthcare providers and patients to ensure that they are used effectively and safely. Training programs and educational materials need to be developed and disseminated to ensure that point of care diagnostics are used appropriately.

The demand for point of care diagnostics is increasing in emerging markets, driven by the rising burden of chronic diseases and improving healthcare infrastructure. Expanding into these markets presents significant growth opportunities for manufacturers and providers of point of care diagnostic tests. Advances in technology and research are leading to the development of new point of care diagnostic tests that are more accurate, sensitive, and specific. Investing in research and development of new tests and technologies presents opportunities for market growth and differentiation.

The market is segmented by product (glucose monitoring, infectious disease testing, cardiac markers, hematology testing, coagulation testing, pregnancy and fertility testing, urinalysis testing, others), mode of delivery (OTC, prescription-based), end-user (professional diagnostic centers, home care settings, research laboratories, others), and geography.

Glucose monitoring kits are one of the largest product segments in the point of care diagnostic market. These kits are used for the management of diabetes and include blood glucose meters and test strips. Infectious disease testing kits are used for the rapid diagnosis of infectious diseases, such as influenza, HIV, and hepatitis. These tests can be performed in a variety of settings, including hospitals, clinics, and community health centers.

Cardiovascular testing kits are used for the diagnosis and management of cardiovascular diseases, such as heart disease and hypertension. These tests include blood pressure monitors, cholesterol test kits, and coagulation tests. Pregnancy and fertility testing kits are used for the rapid and convenient detection of pregnancy and fertility status. These tests include pregnancy test kits, ovulation test kits, and male fertility test kits.

Home care settings are emerging as a significant end-user of point of care diagnostic tests, driven by the increasing demand for self-monitoring and management of chronic diseases, such as diabetes and hypertension. Other end-users of point of care diagnostic tests include research laboratories, academic institutions, and diagnostic testing centers.

Each of these end-user segments presents unique growth opportunities and challenges, depending on factors such as market demand, regulatory environment, and technological advancements. As the point of care diagnostic market continues to grow and evolve, we can expect to see continued innovation and expansion in each of these end-user segments. Additionally, as the healthcare landscape continues to shift towards more patient-centered care, we can expect to see increasing demand for point of care diagnostic tests in home care settings.

Europe is another significant market for point of care diagnostic tests, driven by the increasing demand for rapid diagnosis and treatment, aging population, and the presence of established healthcare infrastructure.

Asia Pacific is emerging as a significant market for point of care diagnostic tests, driven by the increasing prevalence of chronic diseases, improving healthcare infrastructure, and rising healthcare expenditure.

Competitive Analysis

Siemens Healthineers is a global leader in the healthcare industry, offering a range of point of care diagnostic solutions, including diagnostic tests and systems. Danaher Corporation is a diversified global leader in the life sciences and diagnostics industry, with a portfolio of point of care diagnostic products and systems.

Becton, Dickinson and Company is a leading player in the point of care diagnostic market, offering a range of diagnostic tests and systems for the rapid and accurate diagnosis of diseases. Sysmex Corporation is a global leader in diagnostic testing solutions, including point of care diagnostic tests and systems.

In June 2021, Roche Diagnostics announced the acquisition of long-term partner TIB Molbiol, a leading supplier of high-quality PCR and real-time PCR-based research products and assays.

In May 2021, Abbott Laboratories announced the acquisition of Walk Vascular, a privately held medical device company focused on developing minimally invasive solutions for peripheral artery disease.

In April 2021, Becton, Dickinson and Company announced the acquisition of the medical device company Tepha, Inc., which specializes in the development of resorbable polymer technology for surgical applications.

In February 2021, Siemens Healthineers completed the acquisition of Varian Medical Systems, a leading provider of cancer care solutions and services.

In January 2021, Quidel Corporation announced the acquisition of Ellume, a digital diagnostics company focused on developing home-based diagnostic tests for infectious diseases.

In October 2020, Danaher Corporation announced the acquisition of the biopharmaceutical company Cytiva, which specializes in the development of advanced technologies and systems for bioprocessing and cell therapy.

Segmentation Analysis of The Global Neurological Biomaker Market 2022-2030

The report forecasts revenue growth at global, regional, and country matrics and analyzes the latest industry trends in each of the sub-segments ranging from 2016-2030. For this, CDI has segmented the global Point of Care Diagnostics market report based on capacity, vehicle, application, and propulsion type along with regional analysis. 

Product Outlook (Revenue, USD Million, 2018 - 2030)

• Glucose Testing
• Hb1Ac Testing
• Coagulation Testing
• Fertility/Pregnancy
• Infectious Disease
• HIV POC
• Clostridium Difficile POC
• HBV POC
• Pneumonia or Streptococcus Associated Infections

Respiratory Syncytial Virus (RSV) POC

• HPV POC
• Influenza/Flu POC
• HCV POC
• MRSA POC
• TB and Drug-resistant TB POC
• HSV POC
• COVID-19
• Other Infectious Diseases

Cardiac Markers

• Thyroid Stimulating Hormone
• Hematology
• Primary Care Systems

Decentralized Clinical Chemistry

• Feces
• Lipid Testing
• Cancer Marker
• Blood Gas/Electrolytes
• Ambulatory Chemistry
• Drug of Abuse (DOA) Testing
• Urinalysis/Nephrology

End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Clinics
• Pharmacy & Retail Clinics
• Physician Office
• Urgent Care Clinics
• Non-practice Clinics
• Hospitals
• Home
• Assisted Living Healthcare Facilities
• Laboratory

Regional Outlook (Revenue, USD Million, 2017 - 2030)

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Nordic Countries
    • Denmark
    • Finland
    • Iceland
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America